Table 2.
COVID-19 anti-RBD and neutralising antibody before and after two doses of vaccination (n = 50 pairs).
| Type of Antibody | Qualitative Results | Quantitative Results | |||
|---|---|---|---|---|---|
| Before Vaccination | After Vaccination | Before Vaccination | After Vaccination | Folds Elevation | |
| Anti-RBD antibody | 39 (78) | 46 (92) | 38.2 (2.4–122.7) |
3137 (638.3–7748.0) |
65.6 (8.8–248.3) |
| Neutralising antibody | 28 (56) | 43 (86) | 23.0 (11.3–52.0) |
91.3 (63.2–93.3) |
2.7 (1.3–4.7) |
The qualitative and quantitative data are expressed as number (proportion) and median (interquartile range). The titre of the anti-RBD antibody is expressed as U/mL, and neutralising antibody is expressed as %. Qualitative seroconversion was determined based on SARS-CoV-2 anti-RBD antibody titre ≥ 0.80 U/mL.